Hangzhou Tigermed Consulting Co., Ltd.: history, ownership, mission, how it works & makes money

From its founding in 2004 to becoming a global CRO powerhouse, Hangzhou Tigermed Consulting Co., Ltd. has charted rapid growth-listing on the HKEX as 3347.HK in 2012 and expanding to a network of more than 180 offices across five continents with over 10,000 professionals as of December 2025; financially the firm reported total revenue of RMB 6,603 million in 2024 and a net income of RMB 405 million, while maintaining market confidence with a market capitalization near HKD 44.6 billion in 2025-moves highlighted by strategic milestones such as the July 2025 acquisition of Japan's Micron and an MSCI ESG AAA rating in August 2025, all underpinned by dual listings (3347.HK and 300347.SZ), a diversified shareholder base led by co-founder Dr. Xiaoping Ye, and two core service segments-Clinical Trial Solutions and Clinical-related and Laboratory Services-that together deliver medical writing, clinical monitoring, regulatory affairs, pharmacovigilance, imaging, GMP consulting and end-to-end R&D support to biopharma and device clients worldwide

Hangzhou Tigermed Consulting Co., Ltd. (3347.HK): Intro

• 2004 - Company founded in Hangzhou, China, focused on clinical development, regulatory consulting and trial management.
• 2012 - Listed on the Hong Kong Stock Exchange (3347.HK), marking its expansion into international capital markets and enhancing global visibility.
• 2015 - Grew to over 5,000 employees worldwide amid rapid demand for outsourced R&D services.
• 2018 - Achieved a market capitalization of approximately HKD 50 billion, reflecting strong commercial traction and investor confidence.
• July 2025 - Completed acquisition of Micron (Japan), a strategic move to strengthen Asia‑Pacific operations and client coverage.
• December 2025 - Operating more than 180 offices and branches across five continents with a workforce exceeding 10,000 professionals.

• Publicly listed entity on the HKEX under ticker 3347.HK; ownership spread between institutional investors, retail shareholders and corporate insiders.
• Board includes industry and scientific executives overseeing strategy, compliance and M&A (including the 2025 Micron acquisition).
• Subsidiary and regional office network spans EMEA, APAC, North America, Latin America and Greater China to serve global sponsors.

• Mission: Accelerate global drug development by providing integrated, high-quality clinical development services and regulatory support.
• Strategic focus: Expand full-service CRO capabilities, strengthen Asia‑Pacific footprint, invest in digital/real‑world evidence platforms and pursue targeted acquisitions.
• Client mix: International and domestic biopharma sponsors across oncology, CNS, cardiovascular, infectious disease and rare disease therapeutic areas.

• End-to-end clinical development services: protocol development, site management, patient recruitment, data management, biostatistics, medical writing and regulatory submissions.
• Specialized offerings: Phase I-IV clinical operations, real‑world evidence (RWE) studies, pharmacovigilance, biometrics and laboratory services.
• Delivery model: Regional clinical hubs coordinate global programs; centralized quality and regulatory teams ensure compliance across jurisdictions.
• Technology enablement: Electronic data capture (EDC), centralized trial monitoring, risk‑based monitoring and eTMF to reduce timelines and costs.

• Service fees: Fixed‑price and time-and-material contracts for clinical trial management, monitoring, data services and regulatory consulting.
• Project-based revenue: Large development programs and multi-year partnerships generate recurring contract revenue and backlog visibility.
• Value‑added services: Biometrics, lab testing and RWE studies command premium pricing margins versus site-based monitoring.
• M&A and geographic expansion: Acquisitions (e.g., Micron) broaden service mix and create cross‑sell opportunities that lift lifetime client value.

• Global presence: Network of clinical operations and regulatory teams enabling multi-regional trials and local regulatory filings.
• Therapeutic breadth: Capabilities across major and niche therapeutic areas to serve small biotech to large pharma sponsors.
• Talent and capacity: Professional base expanded from ~5,000 (2015) to >10,000 (2025), supporting larger and more complex program delivery.

Hangzhou Tigermed Consulting Co., Ltd. (3347.HK): History

• Public listing: Hong Kong Stock Exchange - 3347.HK.
• Dual-market access: also listed on the Shenzhen Stock Exchange - 300347.SZ.
• Shareholder mix: institutional investors, retail/individual shareholders and company insiders.
• Leadership stake: co‑founder and chairman Dr. Xiaoping Ye maintains a significant ownership position, underscoring long-term management alignment.
• Market capitalisation (2025): approximately HKD 44.6 billion, reflecting investor confidence in the CRO sector and the company's growth trajectory.

• Core model: fee-for-service CRO revenue from clinical trial execution, site management, data management, biostatistics and regulatory submissions.
• Adjacencies: laboratory testing, real‑world evidence studies, post‑market surveillance, and specialized consulting add recurring and project-based income.
• Revenue drivers: higher-complexity trials, biologics and oncology programs, global trial footprints, and long-term partnerships with pharma/biotech clients.
• Profitability levers: scale in operations, higher-margin specialized services, and integration of acquired businesses to improve utilization and pricing power.

Hangzhou Tigermed Consulting Co., Ltd. (3347.HK): Ownership Structure

• Mission: Improve health by accelerating development of innovative and effective treatments for patients worldwide.
• Commitments: Promote efficient pharmaceutical development and provide access to innovative therapies for patients and physicians.
• Values: Integrity, transparency, standardized governance, and ethical business practice.
• Workplace: Cooperative environment emphasizing talent development and a harmonious culture.
• Sustainability: Dedication to ecological integration, symbiotic development, and environmental responsibility.
• ESG recognition: Awarded an MSCI ESG AAA rating in August 2025.

• Institutional investors provide capital and governance scrutiny that enable scale-up of R&D and international trials.
• Insider and management stakes align long-term incentives with clinical quality and sustainable growth.
• Public listing adds transparency, regulatory oversight, and access to capital for geographic expansion and technology investment.

Hangzhou Tigermed Consulting Co., Ltd. (3347.HK): Mission and Values

• Tigermed operates through two main segments: Clinical Trial Solutions and Clinical-related and Laboratory Services.
• The Clinical Trial Solutions segment provides end-to-end R&D support including medical writing, clinical monitoring, regulatory affairs, data management, biostatistics, site management, patient recruitment strategy and project management.
• The Clinical-related and Laboratory Services segment supplies complementary services such as medical imaging, central laboratory coordination, pharmacovigilance (safety monitoring), medical translation, quality assurance (QA), and GMP consulting for manufacturing-related activities.
• The company leverages integrated project teams to bundle services across phases I-IV, adaptive and decentralized trial components, and local regulatory navigation to reduce timelines and complexity-especially for sponsors entering or running trials in China.

• Global workforce: >10,000 professionals across clinical operations, medical affairs, regulatory, data sciences, pharmacovigilance and laboratories.
• Geographic presence: a network of over 180 offices and branches spanning five continents, enabling regional regulatory support, site relationships and on-the-ground monitoring.
• Delivery model: combination of centralized functional hubs (data, biostatistics, medical writing, PV) plus local clinical teams for site-level execution and regulatory liaison.

• Primary revenue streams: fee-for-service contracts across full-study CRO work (protocol design, monitoring, data management, analysis) and specialized clinical-related/lab services sold a la carte or as bundled service packages.
• Value-added margins derive from high-touch clinical monitoring, safety and regulatory consultancy, and proprietary operational platforms that improve trial speed and data quality.
• Growth drivers include rising R&D spend in China, onshoring of global clinical development, demand for local regulatory expertise, expansion of biologics and oncology trials, and increasing outsourcing by domestic innovators.

• Regulatory strategy and local dossier preparation for China's NMPA and regional regulators-high-value advisory that shortens approval timelines.
• Large-scale clinical monitoring and site management capacity, enabling multiple concurrent multi-center trials with scalable margins.
• Centralized data management and biostatistics that permit cross-study efficiencies and reuse of validated workflows and tools.
• Pharmacovigilance and medical safety services that create recurring revenue through long-term safety surveillance agreements.
• Laboratory and imaging coordination that capture ancillary spend around trials (central labs, imaging reads, biomarker testing).

• For global sponsors seeking Chinese patient populations, Tigermed combines local regulatory teams and site networks to compress start-up timelines compared with non-local CROs.
• Integrated service offerings allow clients to consolidate vendors-reducing handoffs and often increasing project-level margins for Tigermed versus one-off consultancy work.
• Investment in pharmacovigilance and data science (centralized safety database and analytics) converts one-time trial fees into recurring safety surveillance and signal-detection contracts post-approval.

Hangzhou Tigermed Consulting Co., Ltd. (3347.HK): How It Works

• Core business model: fee-for-service CRO work across clinical trial management, site operations, monitoring, data services, and clinical-related laboratory testing.
• Clients: multinational and domestic biopharma, biotech, medical device firms, and academic sponsors seeking outsourced development capacity.
• Geographic footprint: China-focused operations with growing international project activity to capture global trials and cross-border sponsors.

• Contract-based revenues: project fees billed by phase (I-IV), trial complexity, therapeutic area, and service scope (e.g., full-service trials, partial services).
• Clinical Trial Solutions: study start-up, site management, monitoring, clinical operations and data management-billing tied to milestones and patient accrual.
• Clinical-related & Laboratory Services: central lab testing, bioanalytical assays, sample logistics and related diagnostics-typically volume- and test-driven revenue.
• Value-added services: regulatory consulting, pharmacovigilance, medical writing and post-marketing study management that add higher-margin workstreams.
• Global projects and partnerships: partnering with overseas sponsors increases contract sizes and recurring engagement potential.

• Service diversification cushions cyclical pressure on any single segment: growth in laboratory services offset declines in trial solutions in 2024.
• Efficiencies and scale: centralized data platforms, in-house labs and standardized SOPs improve margins on high-volume lab testing.
• Investment focus: expanding service lines and international business to capture larger, global trial budgets despite near-term margin pressure.
• Revenue realization: milestone-based billing and per-patient fees create predictable cash conversion for multi-year trials.

• Listed company structure with institutional and retail shareholders via HKEX (3347.HK); governance follows listing rules and standard board oversight.
• Senior management composed of industry veterans from pharma, clinical operations and diagnostics tasked with scaling global capabilities.
• Mission and values: focused on accelerating drug development and improving patient outcomes while expanding service quality and geographic reach; see Mission Statement, Vision, & Core Values (2026) of Hangzhou Tigermed Consulting Co., Ltd.

Hangzhou Tigermed Consulting Co., Ltd. (3347.HK): How It Makes Money

• Core revenue streams: clinical trial operations, laboratory services, regulatory consulting, real-world evidence and post-marketing support.
• Contract mix: predominately fee-for-service with increasing proportion of risk- and milestone-sharing projects for innovative therapies.
• Geographic diversification: China base with accelerating Asia‑Pacific and global projects via a worldwide office network.

• Leading position in China's CRO market, competing among the top national full‑service CROs with deep regulatory expertise and end-to-end capabilities.
• Micron acquisition (July 2025) strengthens regional capacity and client access across Asia‑Pacific, expected to lift cross‑border project volume and service offerings.
• MSCI ESG AAA rating (Aug 2025) highlights institutional recognition of governance, environmental stewardship and social practices - a tailwind for long‑term client and investor confidence.
• Global network of >180 offices supports scalable delivery for multi‑center clinical trials and faster regulatory submissions across jurisdictions.
• Strategic focus on accelerating development of innovative treatments positions the company to capture growth from biologics, cell & gene therapies, and oncology pipelines.

• Clinical operations (largest single contributor): site management, monitoring, data management - billed per-patient/per-study or as project milestones.
• Laboratory & testing services: standardized, higher-repeatability margins from central labs and bioanalytical assays.
• Regulatory & consulting: high‑value advisory fees tied to IND/NDA/MAA submissions and regulatory strategy in China and abroad.
• RWE & post‑marketing: growing recurring revenue from long‑term data programs and lifecycle management contracts.